1. Home
  2. PMAX vs INDP Comparison

PMAX vs INDP Comparison

Compare PMAX & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Powell Max Limited

PMAX

Powell Max Limited

SELL

Current Price

$2.65

Market Cap

4.5M

Sector

N/A

ML Signal

SELL

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.60

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMAX
INDP
Founded
2019
2000
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
4.0M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
PMAX
INDP
Price
$2.65
$2.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.7M
48.7K
Earning Date
09-23-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,799,100.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.56
$1.65
52 Week High
$25.12
$47.60

Technical Indicators

Market Signals
Indicator
PMAX
INDP
Relative Strength Index (RSI) 59.40 50.58
Support Level $2.54 $2.39
Resistance Level $3.35 $2.94
Average True Range (ATR) 0.33 0.26
MACD 0.10 0.11
Stochastic Oscillator 67.60 67.68

Price Performance

Historical Comparison
PMAX
INDP

About PMAX Powell Max Limited

Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: